Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China

• Main Authors: Zhen Feng (Author), Wai Kei Tong (Author), Xinyue Zhang (Author), Zhijia Tang (Author)
• Format: Knjiga
• Izdano: Frontiers Media S.A., 2023-08-01T00:00:00Z.
• Teme: article
• Online dostop: Connect to this object online.

Introduction: Oral semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that improves glycated hemoglobin levels and body weight in patients with type 2 diabetes (T2DM). We aim to evaluate the cost-effectiveness of once-daily oral semaglutide in comparison to placebo and injectable G...